New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
05:55 EDTAVEO, AVEO, CAH, CAH, ABC, ABC, AET, AET, CVS, CVS, BMY, BMY, JPM, JPM, MCK, MCK, CLSN, CLSNCBI to host a forum
6th Annual Forum on Oncology Market Access & Payer Strategies is being held in Philadelphia on January 30-31.
News For MCK;CLSN;AVEO;CAH;ABC;AET;CVS;BMY;JPM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 8, 2014
07:18 EDTBMYInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
07:13 EDTJPMBank dealers agree to revised derivatives rules, FT reports
Subscribe for More Information
06:56 EDTJPMBarclays lists several Large-Cap banks with the most Q3 upside
Subscribe for More Information
06:16 EDTMCKMcKesson initiated with a Buy at Citigroup
Target $235.
October 7, 2014
11:35 EDTJPMStocks with call strike movement; JPM QCOM
Subscribe for More Information
09:17 EDTJPMSecurities Industry & Financial Markets Association to hold a conference
Subscribe for More Information
08:34 EDTBMYBristol-Myers withdrawing NDA for asunaprevir
Given the rapidly evolving hepatitis C treatment landscape in the U.S., Bristol-Myers Squibb has decided that it will not pursue U.S. Food and Drug Administration approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the United States and has therefore withdrawn its new drug application for asunaprevir, an NS3/4A protease inhibitor. The company will continue to pursue FDA approval of daclatasvir, a potent, pan-genotypic NS5A complex inhibitor, which is currently being investigated globally in multiple treatment regimens for HCV patients with high unmet need. Bristol-Myers says "The dual regimen was developed to meet the distinct need of the Japanese patient population, and we believe this treatment has the potential to play a major role in curing HCV patients in Japan, as well as in other markets where the HCV patient population is similar to Japan. In the EU, daclatasvir was recently approved for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of HCV infection in adults. Similarly, we believe that daclatasvir-based regimens have the potential to fill continued unmet medical need in the U.S. and elsewhere in the world. We plan to submit additional data for daclatasvir to the FDA from our ongoing clinical trial program focused on difficult-to-treat patients, including patients with HCV genotype 3, patients who are pre- and post-liver transplant, and patients co-infected with HIV. Next month at the annual meeting of The American Association for the Study of Liver Diseases, we will present new data from several daclatasvir-based regimens. We look forward to bringing daclatasvir to patients in the U.S. and will continue to work closely with the FDA to advance our regulatory application, with the aim of bringing the investigational product to market as quickly as possible."
08:33 EDTBMYBristol-Myers withdrawing NDA for asunaprevir
Subscribe for More Information
07:29 EDTJPMJPMorgan Chase volatility increases into Q3 and guidance
Subscribe for More Information
07:28 EDTJPMWells Fargo ups price target ranges for capital markets banks
Subscribe for More Information
06:51 EDTJPMJustice Department set to attack more large banks by year end, NY Times says
Subscribe for More Information
06:49 EDTJPMBNP seeks assistance from banks as ban approaches, Reuters says
Subscribe for More Information
October 6, 2014
12:22 EDTJPMFireEye risk/reward compelling, says UBS
Subscribe for More Information
08:48 EDTJPMIberdrola hires JPMorgan to sell assets to fund US acquisition, Reuters reports
Iberdrola (IBDRY) has hired JPMorgan (JPM) to sell foreign renewable assets which could raise up to EUR 2B to help fund an acqusition in the U.S., reports Reuters, according to three sources with knowledge of the matter. One financial source said "Iberdrola is not going to sell anything unless they have an adequate acquisition target." Reference Link
08:04 EDTBMYBristol-Myers announces Opdivo clinical trial with Novartis therapies
Subscribe for More Information
08:02 EDTBMYBristol-Myers announces research collaboration to evaluate Opdivo
Subscribe for More Information
07:29 EDTJPMHead of NYDFS reaching out to banks in wake of JPMorgan breach, FT says
Subscribe for More Information
07:12 EDTCAHThe MedTech Conference holds a conference
AdvaMed 2014 is being held in Chicago on October 6-8.
06:27 EDTJPMJPMorgan hackers hit about nine other firms, NY Times says
The group of hackers that infiltrated JPMorgan (JPM) also penetrated about nine other financial institutions, according to The New York Times. Washington intelligence officials and policy makers are much more concerned about the attacks than they have disclosed, the newspaper added. Other publicly traded large banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Publicly traded cybersecurity companies include Barracuda Networks (CUDA), Check Point (CHKP), F5 Networks (FFIV), FireEye (FEYE), Fortinet (FTNT), Imperva (IMPV), Palo Alto (PANW), Proofpoint (PFPT), Qualys (QLYS) and Symantec (SYMC).Reference Link
05:14 EDTBMYNovartis announce clinical collaboration with Bristol-Myers
Novartis (NVS) announced that it has entered into a clinical collaboration with Bristol-Myers Squibb (BMY) to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, Opdivo, in Phase I/II trials of patients with non-small cell lung cancer, or NSCLC. Both studies will be conducted by Novartis. One trial will evaluate the combination of Opdivo with Zykadia, an FDA-approved treatment for patients with anaplastic lymphoma kinase-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib. A second study will investigate Opdivo with INC280, a potent and highly selective inhibitor of c-MET receptor tyrosine kinase, and separately with EGF816, a potent, third-generation EGFR tyrosine kinase inhibitor that is active against T790 mutations. INC280 and EGF816 are currently being investigated in various Phase I/II NSCLC trials. Additional details of the collaboration were not disclosed.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use